Nearwater Capital Markets Ltd Acquires Shares of 20,000 Thermo Fisher Scientific Inc. (NYSE:TMO)

Nearwater Capital Markets Ltd acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 20,000 shares of the medical research company’s stock, valued at approximately $10,405,000.

A number of other large investors have also bought and sold shares of TMO. Barrett & Company Inc. bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $28,000. FPC Investment Advisory Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth about $28,000. Pillar Financial Advisors LLC bought a new position in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Missouri Trust & Investment Co purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $29,000. Finally, Endeavor Private Wealth Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at $30,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TMO. Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. UBS Group dropped their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Raymond James reaffirmed an “outperform” rating and issued a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Finally, Robert W. Baird decreased their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $607.43.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company’s stock, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 14,075 shares of company stock valued at $7,305,942. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $428.88 on Wednesday. Thermo Fisher Scientific Inc. has a twelve month low of $401.75 and a twelve month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $161.90 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 2.99 and a beta of 0.82. The firm’s fifty day simple moving average is $460.85 and its 200 day simple moving average is $513.11.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.11 earnings per share. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.